← Back to Search

Amino Acid

Acetyl-L-Carnitine for Friedreich Ataxia

N/A
Waitlist Available
Led By Theresa A Zesiewicz, MD
Research Sponsored by University of South Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing if a supplement called ALCAR can help people with Friedreich's Ataxia, a condition that affects movement and the heart. The supplement might help their cells make energy better, which could improve heart function and reduce other symptoms. ALCAR has been shown to improve how cells produce energy in various conditions, including aging and heart issues.

Eligible Conditions
  • Friedreich Ataxia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: Acetyl-L-CarnitineExperimental Treatment1 Intervention
Open-label administration of Acetyl-L-Carnitine, up to 2 g/day for 24 months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acetylcarnitine
FDA approved

Find a Location

Who is running the clinical trial?

University of South FloridaLead Sponsor
424 Previous Clinical Trials
189,862 Total Patients Enrolled
3 Trials studying Friedreich Ataxia
62 Patients Enrolled for Friedreich Ataxia
Theresa A Zesiewicz, MDPrincipal InvestigatorUniversity of South Florida
5 Previous Clinical Trials
33 Total Patients Enrolled
1 Trials studying Friedreich Ataxia
4 Patients Enrolled for Friedreich Ataxia
~2 spots leftby Oct 2025